Clinically, ErbB4 somatic mutations have been detected in 19% of melanoma patients (Prickett et al, 2009) and in a variety of other cancer types although at a much lower frequency (1–5% reviewed by Rudloff and Samuels, 2010). Here, ERBB4 is linked to melanoma.